AR099630A1 - Preparación de un inhibidor de mek y formulación que lo comprende - Google Patents

Preparación de un inhibidor de mek y formulación que lo comprende

Info

Publication number
AR099630A1
AR099630A1 ARP130103796A ARP130103796A AR099630A1 AR 099630 A1 AR099630 A1 AR 099630A1 AR P130103796 A ARP130103796 A AR P130103796A AR P130103796 A ARP130103796 A AR P130103796A AR 099630 A1 AR099630 A1 AR 099630A1
Authority
AR
Argentina
Prior art keywords
compound
mixture
formula
solution
suspension
Prior art date
Application number
ARP130103796A
Other languages
English (en)
Inventor
Nichols Paul
J Stengel Peter
Liu Weidong
Zimmermann Daniel
Wolf Marie
Heinz Christine - Pachinger Werner
Andreas Niederer Daniel
Misun Marian
Max Krell Christoph
Original Assignee
Novartis Ag
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50488781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099630(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Array Biopharma Inc filed Critical Novartis Ag
Publication of AR099630A1 publication Critical patent/AR099630A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54Organic compounds
    • CCHEMISTRY; METALLURGY
    • C30CRYSTAL GROWTH
    • C30BSINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/08Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Metallurgy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicación 1: Un proceso para preparar (2-hidroxietioxi)-amida de ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico Compuesto A, de fórmula (4), el proceso comprende los pasos de: a) hacer reaccionar un compuesto de la fórmula (1) con una base adecuada para formar un intermedio; y b) hacer reaccionar dicho intermedio con un compuesto de la fórmula (2) para proporcionar un compuesto de la fórmula (3) o un hidrato de este, donde P¹ es un grupo protector; c) disolver dicho compuesto de la fórmula (3) o un hidrato de este en un solvente o sistema de solventes adecuado; y d) desproteger dicho compuesto de fórmula (3) o un hidrato de este con un reactivo de desprotección adecuado, donde P¹ en cada aparición puede ser el mismo o diferente, y es un grupo protector adecuado, para proporcionar el Compuesto A. Reivindicación 12: El proceso de la reivindicación 1 que comprende adicionalmente las etapas de: a) disolver el Compuesto A en una solución que comprende (i.) un sistema de solventes que comprende un éter y opcionalmente un alcohol y (ii.) agua para proporcionar una solución; b) agregar una suspensión de gérmenes cristalinos a la solución para proporcionar una mezcla de suspensión; c) enfriar la mezcla de suspensión para proporcionar una mezcla de suspensión enfriada; d) agregar agua a la mezcla de suspensión enfriada para proporcionar una mezcla tratada; y e) enfriar la mezcla tratada para proporcionar el Compuesto A cristalizado. Reivindicación 24: Un proceso para preparar (2-hidroxietioxi)-amida de ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico (Compuesto A), el proceso comprende los pasos de: a) disolver el Compuesto A en una solución que comprende (i.) un sistema de solventes que comprende un éter y opcionalmente un alcohol, y (ii.) agua para proporcionar una solución; b) agregar una suspensión de gérmenes cristalinos a la solución para proporcionar una mezcla de suspensión; c) enfriar la mezcla de suspensión para proporcionar una mezcla de suspensión enfriada; d) agregar agua a la mezcla de suspensión enfriada para proporcionar una mezcla tratada; y e) enfriar la mezcla tratada para proporcionar (2-hidroxietioxi)-amida del ácido 6-(4-bromo-2-fluorofenilamino)-7-fluoro-3-metil-3H-benzoimidazol-5-carboxílico cristalizado.
ARP130103796A 2012-10-19 2013-10-18 Preparación de un inhibidor de mek y formulación que lo comprende AR099630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261716169P 2012-10-19 2012-10-19

Publications (1)

Publication Number Publication Date
AR099630A1 true AR099630A1 (es) 2016-08-10

Family

ID=50488781

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130103796A AR099630A1 (es) 2012-10-19 2013-10-18 Preparación de un inhibidor de mek y formulación que lo comprende

Country Status (23)

Country Link
US (7) US9238627B2 (es)
EP (3) EP2909182B1 (es)
JP (3) JP6385939B2 (es)
CN (3) CN109456272A (es)
AR (1) AR099630A1 (es)
BR (1) BR112015008623B1 (es)
CA (2) CA2888474C (es)
CY (1) CY1122670T1 (es)
DK (2) DK2909182T3 (es)
ES (2) ES2971077T3 (es)
FI (1) FI3702351T3 (es)
HK (1) HK1214254A1 (es)
HR (1) HRP20240033T1 (es)
HU (2) HUE047708T2 (es)
JO (1) JOP20130304B1 (es)
LT (1) LT3702351T (es)
PL (2) PL2909182T3 (es)
PT (2) PT2909182T (es)
RS (1) RS65117B1 (es)
RU (2) RU2669391C2 (es)
SI (2) SI2909182T1 (es)
TW (1) TWI650316B (es)
WO (1) WO2014063024A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3702351T3 (fi) 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus
CN105566225A (zh) * 2015-02-16 2016-05-11 苏州晶云药物科技有限公司 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法
SG11201810793XA (en) 2016-06-03 2018-12-28 Giordano Caponigro Pharmaceutical combinations
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
TW201938165A (zh) 2017-12-18 2019-10-01 美商輝瑞股份有限公司 治療癌症的方法及組合療法
US11395823B2 (en) * 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
WO2020212832A1 (en) * 2019-04-16 2020-10-22 Alembic Pharmaceuticals Limited Process of preparation of benzimidazole compounds
WO2021116901A1 (en) * 2019-12-09 2021-06-17 Biocon Limited Forms of binimetinib and process for preparation thereof
MX2023003867A (es) 2020-10-05 2023-04-18 Pf Medicament Combinacion de encorafenib y binimetinib a manera de tratamiento adyuvante contra melanoma resecado en etapa ii.
CN112679438A (zh) * 2020-12-31 2021-04-20 武汉九州钰民医药科技有限公司 制备司美替尼的方法
WO2023084489A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating coronavirus disease 2019
WO2024003942A1 (en) * 2022-07-01 2024-01-04 Natco Pharma Limited An improved process for the preparation of selumetinib sulfate

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0105113A3 (en) * 1999-01-13 2004-11-29 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds
PL352835A1 (en) * 1999-07-16 2003-09-08 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
ES2549159T3 (es) * 2002-03-13 2015-10-23 Array Biopharma, Inc. Derivados de bencimidazol N3-alquilados como inhibidores de MEK
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
EP1904481B1 (en) 2005-06-23 2016-02-17 Array Biopharma, Inc. Process for preparing benzimidazole compounds
US8183385B2 (en) 2005-06-23 2012-05-22 Array Biopharma Inc. SNAR process for preparing benzimidazole compounds
EP1966155A1 (en) * 2005-12-21 2008-09-10 AstraZeneca AB Tosylate salt of 6- (4-br0m0-2-chl0r0phenylamin0) -7-fluoro-n- (2-hydroxyethoxy) -3-methyl-3h-benzimi dazole- 5 - carboxamide , mek inhibitor useful in the treatment of cancer
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
WO2009064675A1 (en) 2007-11-12 2009-05-22 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
CA2761108A1 (en) 2009-04-21 2010-10-28 Novartis Ag Heterocyclic compounds as mek inhibitors
FI3702351T3 (fi) 2012-10-19 2024-01-24 Array Biopharma Inc MEK-inhibiittorin käsittävä koostumus

Also Published As

Publication number Publication date
HRP20240033T1 (hr) 2024-03-29
CA2888474C (en) 2021-03-02
ES2971077T3 (es) 2024-06-03
JP2018135399A (ja) 2018-08-30
CA3079071A1 (en) 2014-04-24
US20160168102A1 (en) 2016-06-16
EP3702351B1 (en) 2023-11-22
EP4306171A3 (en) 2024-04-03
JP6385939B2 (ja) 2018-09-05
US20170231963A1 (en) 2017-08-17
DK2909182T3 (da) 2020-02-17
EP4306171A2 (en) 2024-01-17
JP2016503391A (ja) 2016-02-04
RU2669391C2 (ru) 2018-10-11
HK1214254A1 (zh) 2016-07-22
US9980944B2 (en) 2018-05-29
JP2019194272A (ja) 2019-11-07
CN104870427B (zh) 2018-10-23
EP2909182A4 (en) 2016-07-06
CN104870427A (zh) 2015-08-26
DK3702351T3 (da) 2024-01-29
CY1122670T1 (el) 2021-03-12
EP3702351A1 (en) 2020-09-02
SI3702351T1 (sl) 2024-03-29
US20140128442A1 (en) 2014-05-08
EP2909182A1 (en) 2015-08-26
WO2014063024A1 (en) 2014-04-24
FI3702351T3 (fi) 2024-01-24
JOP20130304B1 (ar) 2021-08-17
RS65117B1 (sr) 2024-02-29
RU2015118572A (ru) 2016-12-20
US20160168104A1 (en) 2016-06-16
CN109456272A (zh) 2019-03-12
JP6737838B2 (ja) 2020-08-12
LT3702351T (lt) 2024-01-10
RU2018127873A (ru) 2019-03-14
BR112015008623B1 (pt) 2022-10-25
US9238627B2 (en) 2016-01-19
SI2909182T1 (sl) 2020-03-31
CN109336824A (zh) 2019-02-15
PL2909182T3 (pl) 2020-06-01
TW201427956A (zh) 2014-07-16
HUE065433T2 (hu) 2024-05-28
US20180296533A1 (en) 2018-10-18
US20160168103A1 (en) 2016-06-16
PL3702351T3 (pl) 2024-04-02
CA3079071C (en) 2022-06-07
US9598376B2 (en) 2017-03-21
BR112015008623A2 (pt) 2017-07-04
CN109336824B (zh) 2022-11-11
PT3702351T (pt) 2024-01-17
HUE047708T2 (hu) 2020-05-28
US9382212B1 (en) 2016-07-05
US10729678B2 (en) 2020-08-04
PT2909182T (pt) 2020-03-02
US9562016B2 (en) 2017-02-07
US20200171002A1 (en) 2020-06-04
EP2909182B1 (en) 2019-12-04
CA2888474A1 (en) 2014-04-24
TWI650316B (zh) 2019-02-11
US10398683B2 (en) 2019-09-03
ES2772498T3 (es) 2020-07-07

Similar Documents

Publication Publication Date Title
AR099630A1 (es) Preparación de un inhibidor de mek y formulación que lo comprende
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
HRP20160241T1 (hr) Postupci i intermedijeri za pripravu jak inhibitora
CO7160029A2 (es) Compuestos de heterociclilo como inhibidores de mek
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
BR112014001801A2 (pt) indazóis
PE20091972A1 (es) Compuestos heterociclicos como inhibidores del factor ixa
ES2526902T3 (es) Procesos de producción de inhibidores de la girasa y topoisomerasa IV
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
RU2014136174A (ru) Способ получения цеолитного материала
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
AR098871A1 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
AR079575A1 (es) Procedimiento para la purificacion de pirazoles
BR112017018580A2 (pt) p-toluenossulfonato para inibidor de mek quinase, e forma cristalina do mesmo e método de preparação para tal
BR112013016637A2 (pt) processo para a preparação de derivados de 3-alquil-sulfinilbenzoíla
AR087344A1 (es) Formas polimorficas del acido 5-(3,3-dimetil-but-1-inil)-3-[(trans-4-hidroxi-ciclohexil)-(trans-4-metil-ciclohexancarbonil)-amino]-tiofen-2-carboxilico y su uso en el tratamiento de la hepatitis c
PE20142331A1 (es) Metodo para preparar un compuesto mediante la reaccion de adicion de michael novedosa usando agua o varios acidos como aditivo
AR089080A1 (es) Proceso de recuperacion de clorhidrato de nalmefeno
AR113853A1 (es) Pirazolopirimidinas que tienen actividad contra el vsr
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina
BR112018076239A2 (pt) método para produzir cristal de composto de ura-cil
PE20130014A1 (es) Hidrato del hidrobromuro de agomelatina y preparacion de este
AR094240A1 (es) Proceso para producir cristal de compuesto de pirazol

Legal Events

Date Code Title Description
FC Refusal